Madeleine King

22.7k total citations · 6 hit papers
304 papers, 14.1k citations indexed

About

Madeleine King is a scholar working on Oncology, Economics and Econometrics and General Health Professions. According to data from OpenAlex, Madeleine King has authored 304 papers receiving a total of 14.1k indexed citations (citations by other indexed papers that have themselves been cited), including 124 papers in Oncology, 103 papers in Economics and Econometrics and 54 papers in General Health Professions. Recurrent topics in Madeleine King's work include Cancer survivorship and care (98 papers), Health Systems, Economic Evaluations, Quality of Life (91 papers) and Childhood Cancer Survivors' Quality of Life (48 papers). Madeleine King is often cited by papers focused on Cancer survivorship and care (98 papers), Health Systems, Economic Evaluations, Quality of Life (91 papers) and Childhood Cancer Survivors' Quality of Life (48 papers). Madeleine King collaborates with scholars based in Australia, United Kingdom and Canada. Madeleine King's co-authors include Richard Norman, Rosalie Viney, Galina Velikova, Phyllis Butow, Rebecca Mercieca‐Bebber, Peter Fayers, Martin R. Stockler, Patricia Kenny, Tim Luckett and Kim Cocks and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Madeleine King

299 papers receiving 13.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30

1996 534 citations Madeleine King Quality of Life Research profile →
A point of minimal important difference (MID): a critique of terminology and methods

2011 477 citations Madeleine King profile →
Evidence-Based Guidelines for Determination of Sample Size and Interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30

2010 469 citations Kim Cocks, Madeleine King et al. Journal of Clinical Oncology profile →
Caring for Aged Dementia Care Resident Study (CADRES) of person-centred care, dementia-care mapping, and usual care in dementia: a cluster-randomised trial

2009 390 citations Madeleine King, Richard Norman et al. profile →
The importance of patient-reported outcomes in clinical trials and strategies for future optimization

2018 372 citations Rebecca Mercieca‐Bebber, Madeleine King et al. profile →
Nursing staffing, nursing workload, the work environment and patient outcomes

2010 372 citations Madeleine King et al. profile →

Peers

Countries citing papers authored by Madeleine King

Since Specialization

Citations

This map shows the geographic impact of Madeleine King's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Madeleine King with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Madeleine King more than expected).

Fields of papers citing papers by Madeleine King

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Madeleine King. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Madeleine King. The network helps show where Madeleine King may publish in the future.

Co-authorship network of co-authors of Madeleine King

This figure shows the co-authorship network connecting the top 25 collaborators of Madeleine King. A scholar is included among the top collaborators of Madeleine King based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Madeleine King. Madeleine King is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Factors associated with the impact of the COVID-19 pandemic on Australians’ daily lives: the role of coping strategies 2025 ·Psychology Health & Medicine ·(unknown), (unknown), (unknown), Madeleine King, Sabina Kleitman	0
2	Danish value sets for the EORTC QLU-C10D utility instrument 2024 ·Quality of Life Research ·Jens Lehmann, (unknown), Morten Aagaard Petersen, Bernhard Holzner, Richard Norman, Madeleine King, Georg Kemmler, (unknown)	7
3	Norwegian and Swedish value sets for the EORTC QLU-C10D utility instrument 2024 ·Quality of Life Research ·Gudrun Rohde, Jens Lehmann, (unknown), (unknown), Bernhard Holzner, Madeleine King, Richard Norman, Georg Kemmler, (unknown)	1
4	A comparison of measurement properties between EORTC QLU-C10D and FACT-8D in patients with hematological malignances 2024 ·Health Economics Review ·(unknown), (unknown), Ling Jie Cheng, Madeleine King, Georg Kemmler, David Cella, Hongjuan Yu, (unknown), Nan Luo	1
5	Valuation of the EORTC Quality of Life Utility Core 10 Dimensions (QLU-C10D) in a Multi-ethnic Asian Setting: How Does Having Cancer Matter? 2024 ·PharmacoEconomics ·Mihir Gandhi, Ravindran Kanesvaran, (unknown), Dawn Q. Chong, (unknown), Rachel Lee-Yin Tan, Richard Norman, Madeleine King, Nan Luo	2
6	A randomised, controlled, multicentre trial of imiquimod versus radiotherapy for lentigo maligna. 2024 ·Journal of Clinical Oncology ·Angela Hong, Serigne Lo, Gerald B. Fogarty, Jonathan R. Stretch, Wei Wang, Pablo Fernández‐Peñas, Richard C. Martin, Matthew Foote, H. Peter Soyer, Jeremy Ruben, Victoria Mar, (unknown), (unknown), Helena Collgros, Amanda Pereira, (unknown), Richard A. Scolyer, Madeleine King, Pascale Guitera	5
7	Patient-reported health-related quality of life outcomes following mastectomy for breast cancer, with immediate, delayed or no breast reconstruction: Four-year follow-up from a prospective cohort study 2023 ·The Breast ·(unknown), Erin Mathieu, Meagan Brennan, Kylie Snook, (unknown), Ian Campbell, (unknown), (unknown), April Wong, Frances Boyle, Madeleine King, Andrew J. Spillane	7
8	Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types 2023 ·European Journal of Cancer ·Jammbe Musoro, Corneel Coens, Mirjam A. G. Sprangers, Yvonne Brandberg, Mogens Grøenvold, Hans‐Henning Flechtner, Kim Cocks, Galina Velikova, Linda Dirven, Elfriede Greimel, Susanne Singer, Katarzyna Pogoda, Eva‐Maria Gamper, Samantha C. Sodergren, Alexander M.M. Eggermont, Michael Koller, Jaap C. Reijneveld, Martin Taphoorn, Madeleine King, Andrew Bottomley	64
9	The Psychology of COVID-19 Booster Hesitancy, Acceptance and Resistance in Australia 2023 ·Vaccines ·Sabina Kleitman, (unknown), (unknown), (unknown), Rachel Campbell, (unknown), (unknown), Jihyun Lee, Lazar Stankov, Madeleine King	10
10	Knowledge translation concerns for the CONSORT-PRO extension reporting guidance: a review of reviews 2022 ·Quality of Life Research ·Rebecca Mercieca‐Bebber, Olalekan Lee Aiyegbusi, Madeleine King, Michael Brundage, Claire Snyder, Melanie Calvert	13
11	Health-related quality of life of Australians during the 2020 COVID-19 pandemic: a comparison with pre-pandemic data and factors associated with poor outcomes 2022 ·Quality of Life Research ·Rebecca Mercieca‐Bebber, Rachel Campbell, (unknown), Sabina Kleitman, Daniel Costa, (unknown), (unknown), Richard Norman, Madeleine King	7
12	The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L 2021 ·Journal of Clinical Epidemiology ·Eva‐Maria Gamper, Francesco Cottone, Kathrin Sommer, Richard Norman, Madeleine King, Massimo Breccia, Giovanni Caocci, Andrea Patriarca, Giuseppe A. Palumbo, Reinhard Stauder, Pasquale Niscola, Uwe Platzbecker, Jo Caers, Marco Vignetti, Fabio Efficace	20
13	Estimation of an EORTC QLU-C10 Value Set for Spain Using a Discrete Choice Experiment 2021 ·PharmacoEconomics ·Aureliano Paolo Finch, Eva‐Maria Gamper, Richard Norman, Rosalie Viney, Bernhard Holzner, Madeleine King, Georg Kemmler, (unknown)	22
14	The role of breast reconstruction choice on body image patient‐reported outcomes at four years post‐mastectomy for breast cancer: A longitudinal prospective cohort study 2021 ·Psycho-Oncology ·(unknown), Erin Mathieu, Meagan Brennan, Kylie Snook, (unknown), Ian Campbell, (unknown), (unknown), April Wong, Frances Boyle, Madeleine King, Andrew J. Spillane	9
15	Evaluation of patient-reported outcome protocol content and reporting in UK cancer clinical trials: the EPiC study qualitative protocol 2018 ·BMJ Open ·Ameeta Retzer, Thomas Keeley, Khaled Ahmed, Jo Armes, Julia Brown, Lynn Calman, (unknown), Fabio Efficace, Anna Gavin, Adam Glaser, David Greenfield, Anne Lanceley, Rachel M. Taylor, Galina Velikova, Michael Brundage, Rebecca Mercieca‐Bebber, Madeleine King, Melanie Calvert, Derek Kyte	7
16	Systematic evaluation of patient-reported outcome (PRO) protocol content and reporting in UK cancer clinical trials: the EPiC study protocol 2016 ·BMJ Open ·Khaled Ahmed, Derek Kyte, Thomas Keeley, Fabio Efficace, Jo Armes, Julia Brown, Lynn Calman, (unknown), Anna Gavin, Adam Glaser, David Greenfield, Anne Lanceley, Rachel M. Taylor, Galina Velikova, Michael Brundage, Rebecca Mercieca‐Bebber, Madeleine King, Melanie Calvert	16
17	Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review 2016 ·BMJ Open ·Rebecca Mercieca‐Bebber, Michael Palmer, Michael Brundage, Melanie Calvert, Martin R. Stockler, Madeleine King	85
18	Psychosocial outcomes in first-generation immigrant cancer patients in Australia 2012 ·The Sydney eScholarship Repository (The University of Sydney) ·Ming Sze, PN Butow, Melanie L. Bell, David B. Goldstein, Madeleine King, Michael Jefford, Afaf Girgis, Maurice Eisenbruch, L. Vaccaro, Skye Dong	1
19	Abstract B32: Unmet needs in Chinese, Greek, and Arabic speaking cancer patients in Australia 2009 ·Cancer Epidemiology and Prevention Biomarkers ·Phyllis Butow, Maurice Eisenbruch, David Goldstein, (unknown), Michael Jefford, (unknown), Afaf Girgis, Madeleine King, (unknown), Ming Sze	4
20	Using Choice Experiments to Estimate QALYs: An Application to Prostate Cancer 2007 ·SSRN Electronic Journal ·Rosalie Viney, Elizabeth Savage, Madeleine King, Ishrat Hossain	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact